The diagnostic and prognostic values of circulating miRNA-1246 in multiple myeloma

Figures & data

Table 1. Characteristics of the study subjects.

Characteristics	MM	HD
Age (years)
≤60	36	12
>60	54	18
Sex
Male	43	14
Female	47	16
R-ISS stage
I/II	48	NA
III	42	NA
Light chain type
Κ	46	NA
Λ	44	NA
Heavy chain type
IgG	39	NA
IgA	32	NA
IgD	2	NA
Kidney injury
Yes	25	ND
No	65	ND
LDH, U/L
≥250	39	ND
<250	51	ND
ALB, g/L
≥35	27	ND
<35	63	ND
β2-MG
<5.5	52	ND
≥5.5	38	ND
Extramedullary infiltration
Yes	10	ND
No	80	ND
Chemotherapy
bortezomib, lenalidomide, dexamethasone (VRD)	34	NA
bortezomib, adriamycin, dexamethasone (PAD)	11	NA
bortezomib, cyclophosphamide, dexamethasone (BCD)	20	NA
bortezomib, dexamethasone (BD)	13	NA
lenalidomide and dexamethasone (RD)	12	NA

Note: NA: not applicable; ND: not detected.

Figure 1. Comparison of the relative expression levels of miR-1246 in MM patients and healthy controls. The expression levels of miR-1246 in the peripheric blood samples of 90 MM patients and 30 health controls were measured by qPCR.

Table 2. Correlation between miR-1246 expression and clinical characteristics of MM patients.

Characteristics	Cases	miR-1246 expression	P-value
Age (years)			0.242
≤60	36	1.67 ± 0.03
>60	54	1.73 ± 0.05
Sex			0.439
Male	43	1.68 ± 0.03
Female	47	1.75 ± 0.02
R-ISS stage			0.102
I/II	48	1.81 ± 0.05
III	42	1.73 ± 0.03
Light chain type			0.241
Κ	46	1.66 ± 0.03
Λ	44	1.72 ± 0.05
Heavy chain type			0.543
IgG	39	1.66 ± 0.04
IgA	32	1.67 ± 0.04
IgD	2	1.66 ± 0.01
kidney injury			0.455
Yes	25	1.55 ± 0.12
No	65	1.62 ± 0.03
LDH, U/L			0.526
≥250	39	1.81 ± 0.04
<250	51	1.86 ± 0.05
ALB, g/L			0.475
≥35	27	1.65 ± 0.14
<35	63	1.72 ± 0.04
β2-MG			0.324
<5.5	52	1.71 ± 0.04
≥5.5	38	1.76 ± 0.05
Extramedullary infiltration			0.009
Yes	10	1.79 ± 0.03
No	80	1.62 ± 0.04

Figure 2. ROC curve analysis of miR-1246 in peripheral blood. The diagnostic value of miR-1246 in MM patients was evaluated by constructing a ROC curve.

Figure 3. Positive expression of miR-1246 was associated with adverse prognosis of MM patients. Kaplan-Meier survival analysis revealed that miR-1246 expression was significantly associated with a shorter OS and PFS of MM patients.

Table 3. Univariate analysis of PFS and OS risk factors in MM patients.

Prognostic parameters	PFS (Month)	P-value	OS (Month)	P-value
Age (years)				0.039
>60	16.0	0.019	24.0
≤60	29.0		55.0
R-ISS stage				<0.001
I/II	28.0	<0.001	55.5
III	13.0		16.0
Chemotherapy				0.042
two drugs	26.5	0.013	26.0
Three drugs	37.5		55.5
Extramedullary infiltration				0.043
Yes	20.0	0.005	23.5
No	31.5		53.5
miR-1246				0.014
>1.67	14.0	0.045	20.5
≤1.67	26.5		55.5

Table 4. Multivariate analysis of PFS and OS risk factors in MM patients.

Prognostic parameter	HR for PFS (95% CI)	P-value	HR for OS (95% CI)	P-value
Age (years)	2.41 (0.91–6.37)	0.071	2.45 (0.72–8.31)	0.148
R-ISS stage	4.32 (1.50–12.39)	0.005	4.84 (1.34–17.56)	0.018
Chemotherapy Regimen	1.66 (0.64–4.28)	0.287	1.67 (1.20–2.25)	0.503
Extramedullary infiltration	2.74 (1.05–7.16)	0.038	4.93 (1.39–17.38)	0.012
miR-1246	2.786 (1.420–5.467)	0.003	2.995 (1.166–7.689)	0.023